New research from the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). This summary is based on a paper published in the journal The Lancet Gastroenterology and Hepatology on June 23, 2026, titled "Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial." 

Read the paper here. 

Learn more about CEGIR: https://cegir.rarediseasesnetwork.org

Transcript: 

Eosinophilic gastritis (EoG) is a rare immune disease that occurs when white blood cells called eosinophils build up in the digestive tract in association with injury and inflammation. For individuals with EoG, this makes eating difficult or even impossible. Heartburn, nausea, vomiting, weight loss, and bloating can be painful and lifelong. However, there are currently no FDA-approved medications for EoG. 

In this study, researchers investigated the use of dupilumab to improve outcomes for individuals with EoG. Forty-one participants with EoG were given dupilumab or a placebo for 12 weeks. Then, researchers evaluated outcomes, including eosinophil counts in the stomach.

Results showed that dupilumab improved the primary outcome and several secondary outcomes, including gastric eosinophil counts, histopathologic and endoscopic abnormalities, and transcriptomic biomarkers compared to the placebo group. Authors note that these findings provide a framework for larger-scale studies and improve understanding of the mechanisms of inflammation in EoG.